Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Abstract Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy thr...

Full description

Bibliographic Details
Main Authors: Jun Lu, Hua Zhong, Jun Wu, Tianqing Chu, Lele Zhang, Hua Li, Qiming Wang, Rong Li, Yizhuo Zhao, Aiqin Gu, Huimin Wang, Chunlei Shi, Liwen Xiong, Xueyan Zhang, Wei Zhang, Yuqing Lou, Bo Yan, Yu Dong, Yanwei Zhang, Baolan Li, Li Zhang, Xiaodong Zhao, Kai Li, Baohui Han
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Advanced Science
Subjects:
anlotinib
liquid biopsies
non‐small cell lung cancer (NSCLC)
stratification
tumor mutation index
Online Access:https://doi.org/10.1002/advs.201900721

Internet

https://doi.org/10.1002/advs.201900721

Similar Items